IMMUNIC, INC. 8-K

What Happened

• Immunic, Inc. (IMUX) held a Special Meeting of Stockholders on April 14, 2026 and obtained shareholder approval to authorize its board to amend the charter to effect a reverse stock split in a ratio between 1-for-10 and 1-for-30.
• The board approved a 1-for-10 reverse stock split of all issued and outstanding common stock, expected to be effective at 12:01 a.m. Eastern Time on April 27, 2026. Post‑split shares are expected to begin trading on Nasdaq under the existing symbol “IMUX” on April 27, 2026.

Key Details

• Shares outstanding as of the record date: 130,464,825.
• Shares present or represented at the Special Meeting: 70,622,667 (≈54.1%).
• Vote totals on the proposal: For 57,404,749; Against 12,594,555; Abstentions 623,363.
• New CUSIP for post-split common stock: 4525EP200.

Why It Matters

• The reverse stock split will reduce the number of outstanding shares by a factor of 10 and increase the per‑share price proportionally; each shareholder’s percentage ownership will remain the same (absent fractional-share adjustments).
• Trading will move to a post‑split basis on Nasdaq when markets open April 27, 2026, so investors should expect to see adjusted share counts and pricing reflected in brokerage accounts that day.
• The filing also contains standard forward‑looking statements about timing; investors should monitor company communications for any updates or details on fractional‑share treatment and administrative procedures.